Influx Healthtech (NSE:INFLUX) Total Receivables: ₹377 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:INFLUX Influx Healthtech Ltd NSE:INFLUX
21 GF Score
Price ₹290.15
! 4 Warning Signs
View Full Analysis

What is Influx Healthtech Total Receivables?

Influx Healthtech NSE:INFLUX -0.29% 21 Total Receivables is ₹377 Mil as of Mar. 2026. GuruFocus rates NSE:INFLUX with a GF Score™ of 21/100. The stock has 4 warning signs investors should review.

Influx Healthtech's Total Receivables for the quarter that ended in Mar. 2026 was ₹377 Mil.

Influx Healthtech Total Receivables Related Terms

Influx Healthtech Total Receivables Historical Data

* Premium members only.

The historical data trend for Influx Healthtech's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Influx Healthtech Total Receivables Chart

Influx Healthtech Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Total Receivables
104.18 140.00 161.22 326.87 377.15

Influx Healthtech Semi-Annual Data
Mar22 Mar23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Receivables Get a 7-Day Free Trial 161.22 0.00 326.87 351.92 377.15
NSE:INFLUX
21GF Score
Influx Healthtech Ltd NSE:INFLUX
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Influx Healthtech Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of ₹377 Mil mean?
Influx Healthtech (NSE:INFLUX) has a Total Receivables of ₹377 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Influx Healthtech and its competitors.
Is Influx Healthtech's Total Receivables too high?
Influx Healthtech's current Total Receivables is ₹377 Mil. Overall, Influx Healthtech has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Influx Healthtech's Total Receivables compare to ZTS and UTHR?
Influx Healthtech's Total Receivables of ₹377 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Influx Healthtech and its competitors. Influx Healthtech's current Total Receivables is ₹377 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Influx Healthtech stock overvalued right now?
Influx Healthtech (NSE:INFLUX) has a current Total Receivables of ₹377 Mil. The current Total Receivables is ₹377 Mil. Influx Healthtech's overall GF Score™ is 21/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Influx Healthtech (NSE:INFLUX), the current Total Receivables is ₹377 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Influx Healthtech Business Description

Address Plot No. 856, 109, Ghanshyam Enclave Premises Co-op Society, Behind Laljipada Police Chowky, Kandivali West, Mumbai, MH, IND, 400067
Influx Healthtech Ltd is a Mumbai-based, healthcare-focused company specialising in contract manufacturing. The company operates manufacturing facilities located in Thane. Its expertise spans the production of Dietary and Nutritional Supplements, Cosmetics, Ayurvedic/Herbal Products, Veterinary Feed Supplements, Homecare Products, Active Pharmaceutical Ingredients (APIs), and finished dosage forms, including tablets, capsules, and injectables. The company generates the majority of its revenue from sale of products.
21GF Score

Get the complete analysis for NSE:INFLUX

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹290.15
Price